Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors.
VANCOUVER, BC / ACCESSWIRE / June 24, 2024 / Eyam is pleased to announce the appointment of Nicholas Franco to its Board of Advisors. Mr. Franco brings a wealth of experience and strategic vision from his extensive career in the pharmaceutical industry.
Mr. Franco has held key executive level leadership positions in several prominent organizations, including his most recent role as Executive Vice President and Chief Business Development Officer at Actelion, a Janssen Pharmaceutical Companies of Johnson & Johnson. His expertise in business development, commercialization and leading organizations has significantly contributed to the growth and innovation in the companies he has served.
With over three decades of experience, Mr. Franco has been pivotal in driving business development and strategic growth in leading pharmaceutical companies, including experience in research, marketing, sales and business development across several therapeutic areas and geographies.
Prior to Janssen, he was the Executive Vice President and Chief Business Officer at Actelion which was later acquired by Janssen in 2017 for $30B. At Novartis, Mr. Franco held several leadership roles including Global Head of Negotiations, Primary Care BD&L, Global Head of Novartis Ophthalmics and Global Head, Neuroscience Business Franchise.
“Eyam is excited to welcome Nicholas as a member of our Advisory Board. His skills, experience and contacts in business development will immediately translate into new opportunities for Eyam’s technologies.”
“I’m excited to join Ryan and the Eyam team in maximizing the value of their innovative self-amplifying oligonucleotide products and technologies to provide physicians better options for difficult-to-treat diseases,” says Nicholas Franco.
Mr. Franco’s appointment aligns with Eyam’s commitment to strengthening its leadership team and maximizing its business development efforts to drive forward its innovative biotech solutions.
About Eyam:
Eyam aims to revolutionize healthcare through the development and commercialization of advanced vaccine and therapeutic platforms. Eyam’s focus includes technologies across four key areas: infectious disease, oncology, chronic disease and animal health.
Eyam, is named in honor of the historic plague village in Derbyshire, England. The residents of Eyam heroically quarantined themselves within the village boundaries to prevent the disease from spreading further, braving near certain death. Today, Eyam honors their heroic sacrifice by advancing next generation technologies to prevent and treat disease on a global scale.
contact info:
Samad Raza,
Business and Data Analyst
sraza@eyamhealth.com
+1 (778) 381-1075
SOURCE: Eyam Vaccines and Immunotherapeutics
View the original press release on accesswire.com
